Update Atherogenese 2015

Abstract

Atherogenesis and its clinical sequelae account for most deaths world-wide. It results from a distorted lipid metabolism and imbalanced immune response. In this review we discuss common and emerging risk factors that lead to plaque formation, the biology behind it, and recent advances and challenges in atherosclerosis therapy.

• Literatur

• 1 Strong JP, Malcom GT, McMahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281: 727-735
• 2 Khot UN, Khot MB, Bajzer CT et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904
• 3 Wolf D, Stachon P, Bode C et al. Inflammatory mechanisms in atherosclerosis. Hamostaseologie 2014; 34: 63-71
• 4 Hilgendorf I, Swirski FK, Robbins CS. Monocyte fate in atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35: 272-279
• 5 Robbins CS, Hilgendorf I, Weber GF et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013; 19: 1166-1172
• 6 Zirlik A, Lutgens E. An inflammatory link in atherosclerosis and obesity. Co-stimulatory molecules. Hamostaseologie 2015; 35: 272-278
• 7 Wolf D, Zirlik A, Ley K. Beyond vascular inflammation-recent advances in understanding atherosclerosis. Cell Mol Life Sci 2015; 72: 3853-3869
• 8 Stone GW, Maehara A, Lansky AJ et al. PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-235
• 9 Ridker PM, Danielson E, Fonseca FA et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207
• 10 Robinson JG, Farnier M, Krempf M et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-1499
• 11 Tardif JC, Tanguay JF, L’Allier PL et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after PCI for non-ST elevation myocardial infarction: results of the SELECT-ACS Trial. J Am Coll Cardiol 2013; 61: 2048-2055
• 12 Morton AC, Rothmann AMK, Greenwood JP et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 2015; 36: 377-384
• 13 Ridker PM, Thuren T, Zalewski A et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597-605
• 14 Anonymous. A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors. Im Internet: https://clinicaltrials.gov/ct2/show/NCT01331837 Stand: 04.11.2015
• 15 Nidorf SM, Eikelboom JW, Budgeon CA et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61: 404-410
• 16 Everett BM, Pradhan AD, Solomon DH et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166: 199-207